Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.


New Drugs and Targets for Asthma and COPD

Hansel T.T. (London) 
Barnes P.J. (London) 

Status: available   
Publication year: 2010
Buy this book
Digital Version: CHF 248.00, EUR 232.00, USD 292.00
Print Version: CHF 248.00, EUR 232.00, USD 292.00
The final prices may differ from the prices shown due to specifics of VAT rules, postage and handling.
Order this title

You already have online access to this title. If you would like to buy a personal digital or print copy, please click here.

This book belongs to
Progress in Respiratory Research , Vol. 39
Editor(s): Herth F.J.F. (Heidelberg) 
XIV + 310 p., 80 fig., 67 in color, 46 tab., hard cover, 2010
Status: available   
ISSN: 1422-2140
e-ISSN: 1662-3932

Reporting the latest progress
Asthma, allergy and chronic obstructive lung disease are common throughout the world and are increasing in incidence, particularly in the developing world.
This volume provides a state-of-the-art account of the identification of new targets and the development of new therapies for these conditions. Some 40 chapters by clinical academics and senior members of the pharmaceutical industry detail the latest breakthroughs in research and development. In asthma, a promising approach is the use of therapy directed against specific Th2 responses through biological antagonists of IL-5, IL-4 and IL-13. There have also been major advances in our understanding of innate immune responses to pathogen-associated molecular patterns, and in the area of Toll-like receptors.

Up to date and comprehensive, this book will be of particular relevance to those working in the pharmaceutical industry (in preclinical research and clinical development), to academic researchers in the field of respiratory medicine, and to respiratory health care specialists.